Jounce Therapeutics, Inc. (NASDAQ:JNCE) went up to recover about 148.5% since recording its record low price of $2.66. The stock experienced -3.78% slump, arriving at $6.61 on 3/14/2019. During the day, the stock price traveled from $6.51 to $7.35. This company shares are 89.11% off its target price of $12.5 and the current market capitalization stands at $221.83M. The recent change has given its price a 49.19% lead over SMA 50 and -76.9% deficit over its 52-week high. The stock witnessed 57.76% gains, 79.13% gains and -7.42% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found JNCE’s volatility during a week at 15.76% and during a month it has been found around 9.52%.

Jounce Therapeutics, Inc. (JNCE) Top Holders

Institutional investors currently hold around $168 million or 73.7% in JNCE stock. Look at its top three institutional owners: Trv Gp Ii, Llc owns $70.28 million in Jounce Therapeutics, Inc., which represents roughly 31.68% of the company’s market cap and approximately 41.83% of the institutional ownership. Similar statistics are true for the second largest owner, Trv Gp Iii, Llc, which owns 3,048,780 shares of the stock are valued at $20.95 million. The third largest holder is Wellington Management Group Llp, which currently holds $10.38 million worth of this stock and that ownership represents nearly 4.68% of its market capitalization.

Jounce Therapeutics, Inc. 13F Filings

At the end of December reporting period, 45 institutional holders increased their position in Jounce Therapeutics, Inc. (NASDAQ:JNCE) by some 1,473,050 shares, 38 decreased positions by 4,002,934 and 16 held positions by 19,041,608. That puts total institutional holdings at 24,517,592 shares, according to SEC filings. The stock grabbed 15 new institutional investments totaling 442,319 shares while 16 institutional investors sold out their entire positions totaling 898,737 shares.

Jounce Therapeutics, Inc. (JNCE) Analyst Guide

Several analysts have released their opinion on Jounce Therapeutics, Inc. (NASDAQ:JNCE), with 1 analysts believing it is a strong buy. Whereas 2 of them predict the stock is a hold. Also, there are 2 buy, 1 sell and 0 strong sell ratings, collectively assigning a 2.5 average brokerage recommendation [T1].